SCHEMBL2158906

SCHEMBL2158906

CC(C)CC(NC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSL P07711 4/20 0.67
CA2 P00918 2/20 0.67
CTSB P07858 2/20 0.67
CA1 P00915 2/20 0.67
CTSS P25774 1/20 0.67
CTSK P43235 1/20 0.67
GRN P28799 4/20 0.65
SORT1 Q99523 4/20 0.65
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
MME P08473 1/20 0.56
DGAT1 O75907 1/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
POLB P06746 1/20 0.56
KMT2A Q03164 1/20 0.56
PSMB5 P28074 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158900 1.00 CTSL (0.67) CTSLCA2CTSBCA1CTSS
SCHEMBL4465251 1.00 CTSL (0.67) CTSLCA2CTSBCA1CTSS
SCHEMBL20277660 0.88 CTSL (0.65) CTSLCA2CTSBCA1CTSS
SCHEMBL1640054 0.88 NAALAD2 (0.58) CTSLCA2CTSBCA1CTSS
SCHEMBL9830474 0.87 PSMB5 (0.72) CTSLCTSBCTSSCTSKMME
SCHEMBL9830466 0.87 PSMB5 (0.72) CTSLCTSBCTSSCTSKMME
SCHEMBL4160513 0.87 CA2 (0.68) CTSLCA2CTSBCA1CTSS
SCHEMBL31611853 0.87 CA2 (0.68) CTSLCA2CTSBCA1CTSS
SCHEMBL17822178 0.87 HPGDS (0.65) CTSLCA2CTSBCA1CTSS
SCHEMBL7432512 0.87 CTSL (0.63) CTSLCA2CTSBCA1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105749890-A Chiral stationary phase prepared by taking cinchonidine-boc-amide as chiral selector as well as preparation method and application thereof 河南科技学院 2016-07-13 CN claimed
CN-105642261-A Chiral stationary phase prepared with cinchonine-Boc-amide as chiral selector and preparation method and application thereof 河南科技学院 2016-06-08 CN claimed
CN-105561959-A Chiral stationary phase prepared by taking quinine-tertiary butyl carbamate as a chiral selector and preparation method and application of chiral stationary phase HENAN INST OF SCIENCE & TECH 2016-05-11 CN claimed
CN-105498736-A Chiral stationary phase prepared by taking quinindium-t-butyl carbamate as chirality selector as well as preparation method and application of chiral stationary phase HENAN INST OF SCIENCE & TECH 2016-04-20 CN claimed
CN-101027092-A Non-absorbent and absorbent articles for inhibiting the production of exoproteins KIMBERLY CLARK CO (US) 2007-08-29 CN claimed
EP-1793871-A2 NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS Kimberly-Clark Worldwide, Inc. (US) 2007-06-13 EP claimed
WO-2006038980-A2 NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2006-04-13 WO claimed
US-20060067991-A1 Non-absorbent articles for inhibiting the production of exoproteins KIMBERLY-CLARK WORLDWIDE, INC. 2006-03-30 US claimed
US-20050090652-A1 Highly homogenous serum albumin as chiral selector NOVOZYMES DELTA LIMITED (GB) 2005-04-28 US claimed
EP-1465847-A1 HIGHLY HOMOGENEOUS SERUM ALBUMIN AS CHIRAL SELECTOR Delta Biotechnology Limited (GB) 2004-10-13 EP claimed
US-20020001591-A1 Compositions for the delivery of antigens EMISPHERE TECHNOLOGIES, INC. 2002-01-03 US claimed
US-5958457-A MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS EMISPHERE TECHNOLOGIES, INC. (US) 1999-09-28 US claimed
EP-0784469-A4 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECH INC (US) 1999-03-24 EP claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN claimed
EP-0784469-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS Emisphere Technologies, Inc. (US) 1997-07-23 EP claimed
WO-1996012474-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-05-02 WO claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020001591-A1 Compositions for the delivery of antigens CD47, CD74, LY96 CTSL 1932/4885CA2 455/4885CTSB 1265/4885
US-20060067991-A1 Non-absorbent articles for inhibiting the production of exoproteins SLC43A1, MRPL21, SLC7A5 CTSL 2689/4885CA2 1875/4885CTSB 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.